High early growth response 1 (EGR1) expression correlates with resistance to anti-EGFR treatment in vitro and with poorer outcome in metastatic colorectal cancer patients treated with cetuximab.

S S KumarY TomitaJ WrinM BruhnA SwallingM MohammedT J PriceJennifer E Hardingham

Published in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2016)

High EGR1 expression may be a candidate biomarker of resistance to anti-EGFR therapy.

Keyphrases

metastatic colorectal cancer
poor prognosis
small cell lung cancer
epidermal growth factor receptor
tyrosine kinase
binding protein
stem cells
squamous cell carcinoma
radiation therapy
combination therapy
bone marrow